The effects of glycation/glycoxidation on the liberation of 8-epi-PGF(2α) from low density lipoprotein during its in vitro oxidation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 62, Issue 4, 2000, Pages 217-224

  Sobal, G ^a   Menzel, E J ^a   Sinzinger, H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ARACHIDONIC ACID; CATION; CHELATING AGENT; COPPER ION; LOW DENSITY LIPOPROTEIN; MEMBRANE PROTEIN; METAL; UNSATURATED FATTY ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; FEMALE; GLYCATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; NORMAL HUMAN; OXIDATION; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; UMBILICAL VEIN;

EID: 0034083546     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2000.0146     Document Type: Article

References (42)

1. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L. Beyond cholesterol: modifications of low- density lipoprotein that increase its atherogenicity. N Engl J Med. 320:1989;915-924.
2. Palinski W., Rosenfeld M. E., Ylä-Herttuala S. LDL undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 86:1989;1372-1376.
3. Ylä-Herttuals S., Palinski W., Rosenfeld M. F. Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man. J Clin Invest. 84:1989;1986-1095.
4. Salonen J. T., Ylä-Herttuala S., Yamamoto R. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
5. Griffin M. E., McInerney D., Fraser A. Autoantibodies to oxidized LDL: the relationship to LDL fatty acid composition on diabetes. Diabet Med. 14:1997;741-747.
6. Festa A., Kopp J., Schernthaner G., Menzel E. J. Autoantibodies to oxidised low-density lipoproteins in IDDM are inversely correlated with severity of disease. Diabetologia. 41:1998;350-356.
7. Lehr H. A., Hübner C., Nolte D. Oxidatively modified LDL stimulates leukocyte adherence to the microvascular endothelium in vivo. Res Exp Med. 191:1991;85-90.
8. Galle J., Mülsch A., Busse R., Bassenge E. Effects of native and oxidized LDL on formation and inactivation of endothelium-derived relaxing factor. Arteriosclerosis Thromb. 11:1991;198-203.
9. Tanner F., Noll C. G., Boulanger C. M., Lüscher T. F. Oxidized low-density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation. 83:1991;2012-2020.
10. Weis J. R., Pitas R. E., Wilson B. D., Rodgers G. M. Oxidized LDL increases human endothelial cell tissue factor activity and reduces protein C activation. FASEB J. 5:1991;2459-2465.
11. Pyorälä K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes. 3:1987;463-524.
12. Kannell W. B., Hjortland M., Castelli W. P. Role of diabetes in cardiac disease: conclusions from population studies: the Framingham Study. Am J Cardiol. 34:1974;29-34.
13. Uusitupa M. I. J., Niskanen L. K., Siitonen O., Voutilainen E., Pyorälä K. 5-years incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and non-diabetic subjects. Circulation. 82:1990;27-36.
14. Kawamura M., Heinecke J. W., Chait A. Pathophysiological concentrations of glucose promote oxidative modification of LDL by a superoxide dependent pathway. J Clin Invest. 94:1994;771-778.
15. Hunt J. V., Smith C. C. T., Wolff S. P. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes. 39:1990;1420-1424.
16. Mullarkey C. J., Edelstein D., Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun. 174:1990;932-939.
17. Hicks M., Delbridge L., Yue D. K., Reeve T. S. Catalysis of lipidperoxidation by glucose and glycosylated collagen. Biochem Biophys Res Commun. 151:1988;649-655.
18. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA. 90:1993;6434-6438.
19. Menzel E. J., Sobal G., Staudinger A. The role of oxidative stress in the long-term glycation of LDL. BioFactors. 6:1997;111-124.
20. Bowie A., Owens D., Collins P., Johnson A., Tomkin G. H. Glycosylated LDL is more sensitive to oxidation: implications for the diabetic patients? Atherosclerosis. 102:1993;63-67.
21. Bucala R., Makita Z., Vega G., Grundy S., Koschinsky T., Cerami A., Vlassara H. Modification of LDL by advanced glycation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA. 91:1994;9441-9445.
22. Tsai E. C., Hirsch I. B., Brunzell J. D., Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes. 43:1994;1010-1014.
23. Morel D. W., Chisholm G. M. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res. 30:1989;1827-1834.
24. Bellomo G., Maggi E., Poli M., Agosta F. G., Bollati P., Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes. 44:1995;60-66.
25. Baby A. V., Gebicki J. M., Sullivan O. R., Willey K. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochem Pharmacol. 43:1992;995-1000.
26. Reaven P. D., Herold D. A., Barnett J., Edelman S. Effects of vitamin E on susceptibility of LDL and LDL subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care. 18:1995;807-816.
27. Feingold K. R., Grunfeld C., Pang M., Doerler W., Krauss R. M. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb. 12:1992;1496-1502.
28. 2-like compounds are produced in vivo in humas by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 87:1990;9383-9387.
29. Morrow J. D., Harris T. M., Roberts L. J. II. Non-cyclo-oxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal Biochem. 184:1990;1-10.
30. 2α-1: an index of lipid peroxidation in humans. Proc Natl Acad Sci USA. 95:1998;3449-3454.
31. 2α, in rabbit lung in situ. Am J Physiol. 263:1992;H660-H663.
32. 2α, a potent agonist of the vascular thromboxanel endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins. 44:1992;155-163.
33. Leitinger N., Blazek I., Sinzinger H. The influence of isoprostanes on ADP-induced platelet aggregation and cyclic AMP generation in human platelets. Thromb Res. 86:1997;337-342.
34. 2αlevels are elevated in individuals with NIDDM. FEBS Lett. 368:1995;225-229.
35. 2-isoprostane biosynthesis in type IIA hypercholesterolemia. J Invest Med. 44:1996;224A.
36. Sato Y., Hotta N., Sakamoto N., Matsuoka S., Ohishi N., Yagi K. Lipid peroxide level in plasma of diabetic patients. Biochem Med. 21:1979;104-107.
37. Jennings P. E., Jones A. F., Florkowski C. M., Lunec J., Barnett A. H. Increased diene conjugates in diabetic subjects with micro-angiopathy. Diabetic Med. 4:1987;452-456.
38. Stringer M. D., Gorog P. G., Freeman A., Kakkar V. V. Lipid peroxides and atherosclerosis. Br Med J. 298:1989;281-284.
39. Lyons T. J., Baynes J. W., Patrick J. S., Colwell J. A., Lopes-Virella M. F. Glycosylation of low-density lipoprotein in patients with Type I (insulin-dependent) diabetes: correlations with other parameters of glycemic control. Diabetologia. 29:1986;685-689.
40. Steinbrecher U. P. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem. 262:1987;3603-3608.
41. 2-isoprostanes during aortic endothelial cell-mediated oxidation of low density lipoprotein. FEBS Lett. 348:1994;297-300.
42. Lynch S., Frei B. Physiological thiol compounds exert pro- and anti-oxidant effects, respectively, on iron- and copper- dependent oxidation of human low-density lipoprotein. Biochim Biophys Acta. 1345:1997;215-221.